Adenovirus-mediated interferon-β gene therapy suppresses growth and metastasis of human prostate cancer in nude mice

Cancer Gene Therapy

Volumn 8, Issue 7, 2001, Pages 497-505

  Cao, Guangwen ^a   Su, Jingdong ^a   Lu, Weixin ^a   Zhang, Fahao ^a   Zhao, Guiling ^a   Marteralli, Daniele ^a   Dong, Zhongyun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenoviral vectors; Angiogenesis; Interferon ; Nitric oxide; Prostate cancer

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BETA GALACTOSIDASE; BETA INTERFERON; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; TRANSFORMING GROWTH FACTOR BETA1; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOVIRIDAE; ANIMALS; ANTIGENS, CD31; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERFERON-BETA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITROPRUSSIDE; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; BACTERIA (MICROORGANISMS); MURINAE; MUS MUSCULUS;

EID: 0034904471     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700333     Document Type: Article

References (57)

1. Cancer statistics, 1999
2. Future prospects in prostate cancer
3. Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-beta
4. Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines
5. Action of spontaneously produced beta interferon in differentiation of embryonal carcinoma cells through an autoinduction mechanism
6. Interferon-beta induces S phase accumulation selectively in human transformed cells
7. Effects of nIFN beta and rIFN gamma on growth and morphology of two human melanoma cell lines: Comparison between two- and three-dimensional culture
8. Role of endogenous interferon-beta in lipopolysaccharide-triggered activation of the inducible nitric-oxide synthase gene in a mouse macrophage cell line, J774
9. Expression of interferon-beta during the triggering phase of macrophage cytocidal activation. Evidence for an autocrine/paracrine role in the regulation of this state
10. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients
11. Enhancement by interferon of natural killer cell activity in mice
12. The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis
13. Inhibition of wound healing in mice by local interferon alpha/beta injection
14. Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas
15. Sensitized T lymphocytes render DBA/2 beige mice responsive to IFN alpha/beta therapy of friend erythroleukemia visceral metastases
16. Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor
17. Intranasal administration of IFN-alpha/beta inhibits the development of visceral tumor metastases
18. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha, beta following cyclophosphamide in mice injected with highly metastatic friend erythroleukemia cells
19. Type I interferon keep activated T cell alive
20. Type I IFNs enhance the terminal differentiation of dendritic cells
21. Differential induction of IL-12 by IFN-beta and IFN-gamma in human macrophages
22. Cytokine therapeutics: Lessons from interferonalpha
23. Pulmonary cavernous hemangiomatosis treated with interferon alfa-2a
24. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Trials Network study
25. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma
26. Interferon-beta treatment of metastatic prostate cancer
27. Why do so many cancer patients fail to respond to interferon therapy?
28. Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice
29. Interferon levels in human pulmonary tumors are lower than plasma levels
30. Distribution of human recombinant interferon-alpha 2 in rat plasma, liver, and experimental liver metastases
31. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers
32. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta
33. Adenovirus-mediated interferon-beta gene therapy eradicates primary tumors and induces systemic immune protection in UV2237m murine metastatic fibrosarcoma
34. Manipulation of adenovirus vectors
35. Metastatic behavior of human tumor cell lines grown in the nude mouse
36. Metastatic model for human prostate cancer using orthotopic implantation in nude mice
37. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation
38. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
39. Suppression of tumorigenicity and metastasis in murine UV-2237 fibrosarcoma cells by infection with a retroviral vector harboring the interferon-beta gene
40. Flow cytometric characterisation of proliferating cell nuclear antigen using the monoclonal antibody PC10
41. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: Role of macrophage-inducible nitric oxide synthase
42. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with the murine IFN-beta gene: Possible role of nitric oxide
43. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice
44. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide
45. Destruction of bystander cells by tumor cells transfected with inducible nitric oxide (NO) synthase gene
46. Role of nitric oxide in lysis of tumor cells by cytokine-activated endothelial cells
47. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells
48. Activation of nitric oxide synthase gene for inhibition of cancer metastasis
49. Transforming growth factor-beta in benign and malignant prostate
50. Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: The role of platelet-derived growth factor
51. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases
52. Transforming growth factor-beta1 serum concentration in patients with prostatic cancer and benign prostatic hyperplasia
53. Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion
54. Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells
55. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in tumor cells. Implications for tumor development
56. Synthesis and biological effects of NO in malignant glioma cells: Modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer